Skip to main content

Table 17 Characteristics of included studies- thyroid cancer

From: Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies

Study source

Sex

Study period

Source of subjects

No of case

No of control/cohort size

Cancer site

Exposure assessment

Exposure Definition

Adjustment for covariates

Study quality

Cohort studies

 Patel D [234], 2015, US

M/F

1993–2001

AARP

292

269,553

Thyroid cancer

Questionnaires

Use aspirin ≤ 2 times/Week(no regular use)

2,3,6,8,11

7

   

PLCO

56

58,433

Thyroid cancer

Questionnaires

Use aspirin ≤ 2 times/Week(no regular use)

2,3,6,8,11

6

   

U.S. Radiologic Technologists Study

133

60,591

Thyroid cancer

Questionnaires

Use aspirin ≤ 2 times/Week(no regular use)

2,3,6,8,11

6

 Brasky TM [92], 2014, US

F

1998–2010

WHI

229

142,330

Thyroid cancer

Questionnaires

Use at both baseline and year 3 visits (consistent)

1,3,4,5,6,7,9,10,11,12,13,14,15,16,17,18,19,22,24,25,26,27,28,29,30,31,32,33,34,35,36,37

9

  1. 1 = age, 2 = sex, 3 = smoking, 4 = education level, 5 = family history, 6 = alcohol intake, 7 = height, 8 = weight, 9 = history of ulcer, 10 = BMI, 11 = race, 12 = duration of estrogen therapy, 13 = duration of combined postmenopausal hormone therapy, 14 = hysterectomy status, 15 = use of antihypertensive medication, 16 = history of coronary heart disease, 17 = use of cholesterol-lowering medication, 18 = physical activity, 19 = fruit, vegetable and/or vitamin intake, 20 = history of colonoscopy, 21 = total energy intake, 22 = ever use of calcium supplements in the past 5 years, 23 = former health checkup, 24 = red meat, 25 = hormone replacement therapy, 26 = gravidity, 27 = history of arthritis, 28 = age at first birth, 29 = other NSAIDs, 30 = area (county/region), 31 = migraine, 32 = Nitro-vasodilator use, 33 = observational study enrollment, 34 = diet modification trial enrollment, 35 = screening for cancer, 36 = age at menarche, 37 = age at menopause
  2. AARP AARP diet and health study, PLCO prostate, lung, colorectal and ovarian cancer screening trial, WHI women’s health initiative